ArticleOncology letters2023
Immunohistochemical expression of TROP‑2 (TACSTD2) on the urothelial carcinoma of the urinary bladder and other types of cancer.
Article in Oncology letters, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 16 citations in OpenAlex.
- Disease stage-dependent expression of ADC-related biomarkers in urothelial carcinoma.Translational andrology and urology · 2026Article
- SOX2-positive upper tract urothelial carcinoma: Clinicopathological characteristics and therapeutic implications.Oncology letters · 2026Article
- Structure and function of therapeutic antibodies approved by the US FDA in 2025.Antibody therapeutics · 2026Review
- Expression of Nectin-4 and Trop-2 in upper tract urothelial carcinoma: implications for biomarker-driven antibody-drug conjugate therapy.The journal of pathology. Clinical research · 2026Article
- The emerging role of TROP2 as a diagnostic and prognostic biomarker in bladder tumor.Cancer cell international · 2026Review
- Exploring the Therapeutic Potential of TROP2 Gene Silencing in Hepatocellular Carcinoma.Recent patents on biotechnology · 2026Article
- Modulating the PPARγ pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer.Nature communications · 2025Article
- Neoadjuvant treatment patterns and biomarker selection in muscle-invasive bladder cancer.Discover oncology · 2025Review
- Optimizing enfortumab vedotin plus pembrolizumab therapy.Oncotarget · 2025Review
- Integrating analysis of multi-omics summary data identifies novel plasma protein biomarkers and drug targets for bladder cancer.Discover oncology · 2025Article
- Trop-2 and Ephrin B2 expression in urothelial carcinoma with divergent differentiation and aggressive urothelial carcinoma subtypes.American journal of clinical pathology · 2025Article
- ImmunoPET Imaging of Trop2 Expression in Bladder Cancer Using [Molecular pharmaceutics · 2025Article
- Overcoming resistance in advanced urothelial carcinoma: mechanisms of escape from antibody-drug conjugates and FGFR3 inhibition.Frontiers in oncology · 2025Review
- [American journal of nuclear medicine and molecular imaging · 2025Article
- TROP2-targeted molecular imaging: a promising tool for precision oncology.American journal of nuclear medicine and molecular imaging · 2025Review
- Are primary tumors suitable for biomarker-guided treatment of metastatic urothelial cancer?Translational andrology and urology · 2024Article
- TROP2 Expression in Bladder Transurethral Resection Specimens: Correlation With Histological Grade and Survival.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In metastatic or locally advanced urothelial carcinoma (UC), therapeutic options have been limited to chemotherapy and immune checkpoint inhibitors. Novel targets and drugs such as antibody drug conjugates have been developed, and enfortumab vedotin targeting nectin-4 and sacituzumab govitecan (SG) targeting trophoblast cell surface antigen 2 (TROP-2), the protein product of the TACSTD2 gene, have been approved. The expression of TROP-2 was investigated within UC and other types of carcinomas, and within the tissue of different healthy organs to understand treatment responses and toxicities. The expression of TROP-2 in the tissues of 42 patients with UC, 13 patients with other types of cancer and in the normal tissues of 11 patients was retrospectively analyzed. Immunohistochemical staining of the TROP-2 protein was performed on a BenchMark ULTRA IHC/ISH System (Roche Tissue Diagnostics; Roche Diagnostics, Ltd.) according to accredited staining protocols in a routine immunohistochemistry accredited and certified facility of the laboratory of immunohistochemistry at the Institute of Pathology (Gerhard-Domagk Institute)- University Hospital Muenster (UKM)-Muenster-Germany]. Different expression levels of TROP-2 were observed, and the highest expression rate of TROP-2 was observed in UC, independent of the tumor stage. However, normal urothelial cells had similar expression levels. Except for ductal carcinoma
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.